Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 2
1992 2
1993 2
1994 3
1995 1
1997 2
1998 3
1999 6
2000 1
2001 1
2004 1
2005 6
2006 7
2007 7
2008 4
2009 8
2010 7
2011 8
2012 4
2016 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy.
Kleinberg L. Kleinberg L. Patient Prefer Adherence. 2016 Nov 24;10:2397-2406. doi: 10.2147/PPA.S93020. eCollection 2016. Patient Prefer Adherence. 2016. PMID: 27920506 Free PMC article. Review.
Polifeprosan 20 with carmustine (GLIADEL()) polymer implant wafer is a biodegradable compound containing 3.85% carmustine (BCNU, bischloroethylnitrosourea) implanted in the brain at the time of planned tumor surgery, which then slowly degrades to release the BCNU ch …
Polifeprosan 20 with carmustine (GLIADEL()) polymer implant wafer is a biodegradable compound containing 3.85% carmustine (BCN …
Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.
Kleinberg L. Kleinberg L. Core Evid. 2012;7:115-30. doi: 10.2147/CE.S23244. Epub 2012 Oct 26. Core Evid. 2012. PMID: 23118709 Free PMC article.
The Polifeprosan 20 with carmustine (BCNU, bis-chloroethylnitrosourea, Gliadel()) polymer implant wafer is a biodegradable compound containing 3.85% carmustine which slowly degrades to release carmustine and protects it from exposure to water with resultant hydrolys …
The Polifeprosan 20 with carmustine (BCNU, bis-chloroethylnitrosourea, Gliadel()) polymer implant wafer is a biodegradable com …
Management of glioblastoma.
Aoki T, Hashimoto N, Matsutani M. Aoki T, et al. Expert Opin Pharmacother. 2007 Dec;8(18):3133-46. doi: 10.1517/14656566.8.18.3133. Expert Opin Pharmacother. 2007. PMID: 18035958 Review.
Eosinophilic meningitis triggered by implanted Gliadel wafers: case report.
Saito K, Yamasaki K, Yokogami K, Ivanova A, Takeishi G, Sato Y, Takeshima H. Saito K, et al. J Neurosurg. 2017 Jun;126(6):1783-1787. doi: 10.3171/2016.4.JNS152771. Epub 2016 Jun 10. J Neurosurg. 2017. PMID: 27285546
A drug lymphocyte stimulation test against the Gliadel wafers failed to demonstrate a positive reaction; polifeprosan, the wafer matrix without 1,3-bis(2-chloroethyl)-1-nitrosourea, yielded a positive reaction. These findings strongly suggest that although extremely rare, …
A drug lymphocyte stimulation test against the Gliadel wafers failed to demonstrate a positive reaction; polifeprosan, the wafer matr …
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME. Weingart J, et al. J Clin Oncol. 2007 Feb 1;25(4):399-404. doi: 10.1200/JCO.2006.06.6290. J Clin Oncol. 2007. PMID: 17264335 Free PMC article. Clinical Trial.
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.
Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H. Attenello FJ, et al. Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18. Ann Surg Oncol. 2008. PMID: 18636295 Clinical Trial.
BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival. ...For patients receiving Gliadel for GBM, median survival was 13.5 mont …
BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade …
Chemotherapy wafers for high grade glioma.
Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Hart MG, et al. Cochrane Database Syst Rev. 2011 Mar 16;2011(3):CD007294. doi: 10.1002/14651858.CD007294.pub2. Cochrane Database Syst Rev. 2011. PMID: 21412902 Free PMC article. Review.
Localized BCNU chemotherapy and the multimodal management of malignant glioma.
La Rocca RV, Mehdorn HM. La Rocca RV, et al. Curr Med Res Opin. 2009 Jan;25(1):149-60. doi: 10.1185/03007990802611935. Curr Med Res Opin. 2009. PMID: 19210148 Review.
However, over the last 10 years only two chemotherapeutic agents have received regulatory approval for treatment of MG: polifeprosan 20 with carmustine (BCNU implant) and temozolomide (TMZ), an imidazotetrazine derivative of dacarbazine. ...
However, over the last 10 years only two chemotherapeutic agents have received regulatory approval for treatment of MG: polifeprosan …
[Local antitumor treatments].
Menei P, Metellus P. Menei P, et al. Neurochirurgie. 2010 Dec;56(6):483-5. doi: 10.1016/j.neuchi.2010.07.012. Epub 2010 Sep 24. Neurochirurgie. 2010. PMID: 20869735 Review. French.
73 results